Pembroke Management, LTD Castle Biosciences Inc Transaction History

Pembroke Management, LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 26, 2022	SELL	$16.0 - $45.99 $7.42 Million - $21.3 Million	-463,909 Closed	0 $0
Q1 2022 May 06, 2022	BUY	$33.17 - $46.98 $2.67 Million - $3.78 Million	80,537 Added 21.01%	463,909 $20.8 Million
Q4 2021 Feb 09, 2022	SELL	$39.06 - $67.58 $1.96 Million - $3.4 Million	-50,307 Reduced 11.6%	383,372 $16.4 Million
Q3 2021 Nov 08, 2021	SELL	$60.13 - $77.6 $1.04 Million - $1.34 Million	-17,215 Reduced 3.82%	433,679 $28.8 Million
Q2 2021 Aug 11, 2021	SELL	$50.07 - $76.78 $517,122 - $792,983	-10,328 Reduced 2.24%	450,894 $33.1 Million
Q1 2021 May 06, 2021	BUY	$58.92 - $97.33 $11.8 Million - $19.6 Million	200,976 Added 77.23%	461,222 $31.6 Million
Q4 2020 Feb 05, 2021	BUY	$43.6 - $73.05 $11.3 Million - $19 Million	260,246 New	260,246 $17.5 Million

202

26M

303K

30.3K

Ticker CSTL
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 26,297,000
Market Cap $759M
Description
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...

Get notified when there are updates to the investment portfolio of Pembroke Management, LTD, based on Form 13F filings with the SEC.

Stay updated on Pembroke Management, LTD with notifications on news.